Colorectal cancer (CRC) is one of the most frequent and deadly cancers in the western world with more than 1.2 million yearly diagnoses and ∼600 000 deaths each year ([@bib68]). Patient survival is largely dependent on early diagnosis and intervention. Accordingly, there is an urgent need for novel diagnostic parameters as well as molecular determinants of clinical outcome, which would allow for the targeted treatment of patients at risk of relapse. Especially in stage II patients, the identification of biomarkers predicting the recurrence of the disease is an unmet clinical need. By using a variety of resources, we previously demonstrated that the suppressor of cytokine signalling 2 serves as a promising marker with a strong prognostic value for early CRC stages ([@bib41]).

Myosins constitute a superfamily of actin-dependent molecular motors that are involved in a large number of essential cellular functions, such as cell motility, endocytosis, vesicle trafficking, and protein/RNA localisation ([@bib53]). In the intestine, myosins are responsible for supporting the apical brush in enterocytes, leading to the emergence of polarised differentiated epithelial cells that possess an apical and a basolateral domain. Myosin Vb (MYO5B) is a class V member of non-conventional myosins, which provide a molecular basis for the transport of actin-dependent organelles and regulate membrane traffic in polarised epithelial cells ([@bib70]). Loss-of-function mutations in the *MYO5B* gene lead to a disruption in cell polarity and the absence of microvilli at the enterocyte surface. This condition, which is known as microvillus inclusion disease (MVID), is a rare disorder that affects newborn infants during their first months, leading to malabsorption and potentially life-threatening marked diarrhoea ([@bib49]). Some of the associated mutations have been proposed to affect MYO5B expression levels via nonsense-mediated RNA decay ([@bib66]).

Members of the Rab family small GTPases, consisting of RAB8 and RAB11, have recently been suggested to act as potential mediators in MYO5B-mediated vesicle transport ([@bib14]; [@bib29]; [@bib58]). In mammalian cells, the RAB11 family consists of three proteins: RAB11A ([@bib5]; [@bib22]), RAB11B ([@bib37]), and RAB25 ([@bib21]). Rab GTPases function as molecular switches and the GTP-bound active conformation recruits effector proteins, such as MYO5B, that operate specifically for different membrane traffic steps ([@bib58]). Whereas some RABs bind indirectly through adapters, others, such as RAB8A and RAB11A, interact directly with MYO5B: MYO5B has specific binding regions in its tail domain and interacts with RAB8A via exon C (exon 30), and with RAB11A via the globular tail ([@bib27]; [@bib39]; [@bib59]). MYO5B thereby functions as a dynamic tether for both RAB8A and RAB11A, and normally maintains these proteins at their appropriate subapical membrane localisation.

Loss of epithelial architecture and cell differentiation/polarity have been shown to be intimately linked to cancer ([@bib60]). Accordingly, emerging evidence suggests that myosins have a crucial role and are differentially expressed in several cancer types ([@bib53]; [@bib42]). On the basis of its role in cell polarisation ([@bib49]; [@bib35]), we hypothesised that MYO5B might be involved in CRC. Along this line, decreased expression of MYO5B was found in gastric cancer ([@bib12]). In the present study, we examined the expression, methylation, and mutational status of *MYO5B* and its adapter proteins in primary colorectal tumours, precursor lesions, and distant normal tissue. We show that MYO5B expression is lost during tumour progression and that a gene expression signature composed of either *MYO5B* alone or in combination with its adapter *RAB8A* displays very strong prognostic value, thereby demonstrating its relevance as a potential prognostic marker in CRC.

Materials and methods
=====================

Patients and samples
--------------------

All human tissue samples used in this study were donated freely, and written informed consent as well as ethical approval from the 'Comité National d'Ethique de Recherche du Luxembourg' (Reference 201009/09) and from the Institutional Ethics Review Panel (ERP-16-032) were obtained. Primary CRC and matched distant non-neoplastic colorectal tissue samples (at the furthest longitudinal surgical margin) were collected at the Hospital Emile Mayrisch by the Integrated Biobank of Luxembourg (IBBL, [www.ibbl.lu](http://www.ibbl.lu)) following the standard preanalytical protocol for biospecimens ([@bib2]). Samples were immediately stored in liquid nitrogen after surgical excision. Our CRC cohort was composed of 74 CRC patients and is described in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. The histopathological data was provided by a pathologist in a blinded way and further confirmed by an independent second pathologist from the 'Laboratoire national de santé'. Out of the 74 samples analysed in this study, 16 were of rectum origin, of which 10 corresponding patients had received radiotherapy alone or in combination with chemotherapy before surgical removal of the tumour. The other remaining 58 patients presented a tumour of the colon, none of them had a treatment before tumour resection. As we did not detect any differences in MYO5B expression between colon- and rectum-derived tumours, we decided to assess them altogether as colorectal tumours. The cohort includes stage I (*n*=10), II (*n*=34), III (*n*=24), and IV (*n*=6) tumour samples, classified according to the TNM Classification of Malignant Tumours (TNM system, American Joint Committee on Cancer) ([@bib28]) staging system, as well as 74 normal tissue samples matching the corresponding tumour ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). We complemented our CRC collection with 46 tumour specimens from the Ontario Tumour Bank (Ontario Institute for Cancer Research).

Materials
---------

All CRC cell lines were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA) and maintained in recommended culture conditions. For methylation analysis, cells were treated with 5 *μ*[m]{.smallcaps} 5-Aza-2\'-deoxycytidine (5-aza-dC/DAC, Sigma-Aldrich, Overijse, Belgium) or vehicle (DMSO) for 4 days followed by RNA extraction.

Tissue preparation and lysis, RNA/DNA extraction, and RT--qPCR
--------------------------------------------------------------

Tissue processing and laser microdissection (LMD) were performed as previously described ([@bib41]). AllPrep extraction kit (Qiagen, Venlo, Netherlands) was used to extract RNA and DNA from microdissected samples. cDNA was obtained via reverse transcription by using a high-capacity cDNA reverse transcription kit (Applied-Biosystems, Thermo-Fisher Scientific, Gent, Belgium). The Experion automated electrophoresis system (Bio-Rad Laboratories, Temse, Belgium) was used to check for RNA quality, which was of acceptable quality for all primary samples. The expression of *MYO5B* was investigated using TaqMan chemistry-based primer/probe sets that are recommended for the use of RNA from microdissected samples ([@bib13]) ([Supplementary Table 2](#sup1){ref-type="supplementary-material"} for reference numbers). PCR conditions were used as previously described ([@bib41]) and the expression levels of the gene of interest were normalised against the housekeeping gene *HPRT1* ([@bib13]). For bulk tissue and CRC cell lines, the RNA was extracted with the miRNeasy kit from Qiagen and cDNA was obtained with the miScript II (Qiagen). PCR cycling conditions as well as quality control and normalisation steps were done in qBase+ (Biogazelle, Gent, Belgium), using two reference genes as previously described ([@bib57]; ([@bib73]). Primer sequences are listed in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}.

Tissue microarrays, immunohistochemical, and western blot analysis
------------------------------------------------------------------

First, the specificity of a selected MYO5B antibody (HPA040902, Sigma-Aldrich) was verified by a knockdown experiment. Briefly, HCT116 and HCT15 cells were transduced (MOI=5) with a pool of three target-specific short hairpin RNA constructs against MYO5B (sh MYO5B sc-75853-V, sh scramble sc-108080, Santa Cruz Biotechnology, Heidelberg, Germany), which resulted in a marked reduction in the expression of MYO5B in both cell lines on mRNA and protein levels ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). For immunoblotting, proteins were subjected to SDS--PAGE (6%) and probed with anti-Stat3 (sc-482, Santa Cruz Biotechnology) as loading control as previously described ([@bib73]. Next, to mimic the condition of a tissue microarray (TMA), cells were clotted with a mix of thrombin/plasma and embedded in paraffin. Sections were cut and stained with the MYO5B antibody used in the TMA. The MYO5B signal intensity was highly reduced in cells after stable knockdown of MYO5B ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}).

The TMA blocks were prepared using 74 primary CRC formalin-fixed paraffin-embedded tumour samples as well as their paired normal colon counterparts. Two punches, 1 mm in diameter, were taken from each donor block providing two spots of both tumour and normal control tissue. The punching of tissue cores and their transfer to the receiver block were done using a 3D Histech TMA arrayer (Sysmex, Budapest, Hungari). Immunohistochemical staining was done on an automated Benchmark XT device (Ventana, Tucson, Arizona, USA) using the CC1M antigen retrieval protocol (Cell conditioning 1 buffer, basic pH and *M*=30 min). Primary antibody against MYO5B was used at a 1 : 50 dilution, with an incubation time of 32 min. The secondary antibody was retrieved from an UltraView DAB detection kit (Ventana). Tissue sections were analysed and a pathologist blindly scored MYO5B staining as follows: 0 (no signal), 1 (low signal), 2 (moderate signal) or 3 (strong signal). Two sections of cancerous as well as normal counterpart tissue were scored per patient and the mean value was considered.

Bioinformatic meta-analysis
---------------------------

We have set up a meta-analysis and used it as previously described ([@bib41]). Briefly, we integrated all the individual CEL files from selected data sets profiled on HG-U133 plus 2.0 (Affymetrix, Santa Clara, CA, USA), retrieved from GEO (GSE14333, GSE17538, GSE21510, GSE8671, GSE9254, GSE20916, GSE10714, GSE15960, GSE4183, and GSE10961) and corresponding to different studies ([@bib61]; [@bib17], [@bib18], [@bib19]; [@bib40]; [@bib54]; [@bib30]; [@bib63]; [@bib64]; [@bib71]) into one single global analysis covering expression data on 829 patients. The suitability of potential markers to discriminate between CRC and normal colorectal samples was assessed by ROC curves as previously described ([@bib41]).

Methylation analysis
--------------------

For monitoring of the methylation pattern of the entire *MYO5B* promoter, methylation analysis using MassARRAY technology (Sequenom) was performed at Varionostics GmbH, Ulm, Germany as previously described ([@bib41]). To further investigate the methylation of *MYO5B*, we used the TCGA data set for CRC (COAD project) with the R package *TCGAbiolinks* ([@bib7]). Among the 456 patients with expression data ('Gene Expression Quantification' as data.type), 295 patients were investigated for DNA methylation (with the platform 'Illumina Human Methylation 450'). RNA expression and DNA methylation were joined according to the patient ID, tissue origin, tumour stage, and gene symbol.

Identification of somatic mutations
-----------------------------------

Data on somatic mutations were retrieved for 399 patients using *TCGAbiolinks* with the MUTECT pipeline (function: GDCquery_Maf ('COAD', pipelines='mutect')). One patient had 5 mutations, one 4 mutations, two 2 mutations, and fourteen 1 mutation. Even if the COSMIC IDs are present in the TCGA data set, the COSMIC database ([@bib16]) contains additional somatic mutations. Version 81 of COSMIC was used to download mutations in *MYO5B*. Five additional somatic mutations are referenced for TCGA patients, however the predicted consequences are missing. In total, 33 somatic *MYO5B* mutations were found in a total of 20 patients. All mutations are displayed on the lolliplot (Figure 3D) and their potential implications highlighted in [Supplementary Table 3](#sup1){ref-type="supplementary-material"}. The evaluation of potential structural and/or functional effects is based on existing structures of MYO5A and MYO5B (PBD entry codes: 4LNZ, 4LX0, 1OE9, and 2DFS) ([@bib9]; [@bib43]; [@bib55]; [@bib76]).

Survival analyses
-----------------

Normalised gene expression values from three different microarray studies with the accession number GSE39582 ([@bib46]), GSE24551 ([@bib1]), and GSE2881 ([@bib44]), and containing clinical data on the outcome of CRC patients were retrieved from GEO using the R package *GEOquery* (v2.40 ([@bib10])). For gene symbols with multiple probe set assignments, we selected the probe set with the largest interquartile range per gene, as suggested in [@bib62]). The retained probe sets for the genes of interest were as follows: *MYO5B*, 225299_at; *RAB8B*, 222846_at; *RAB10*, 222981_s\_at; *RAB11A*, 234998_at; *RAB11B*, 34478_at; *CDC42*, 208727_s\_at; *RAC1*, 1567458_s\_at; and *RHOA*, 1555814_a\_at. *RAB25* only had one probe set assignment. Survival curves were generated using the R package *survival* (v2.41-2 ([@bib67])) and plotted with the R package *survminer* (v0.3.1 ([@bib31])). The continuous log~2~ expression was separated into two discrete categories ('high' and 'low'), separated according to the median *MYO5B* expression value. Of note, the median value was assigned to the 'high' category for odd-numbered data sets.

Combined gene signatures
------------------------

To combine several genes, the log~2~ expression of the six retained genes (*MYO5B*, *RAB8A*, *RAB9A*, *RAB10*, *RAB11A*, and *RAB25*) or nine retained genes (the latter six combined with *CDC42, RAC1*, and *RHOA*) was mean-centred and scaled using the *scale()* function to make them comparable. Then, for each of the 63 or 511 combinations, respectively, scaled expressions were combined following the PROGgene procedure ([@bib23]). Briefly, the six or nine scaled values were averaged to obtain only one gene expression signature value for each patient. The gene signature values were divided into 'high' and 'low' groups using the median as described above. Hazard ratios were computed using the *coxph()* function and ranked by the inferred estimates. Differences between Kaplan--Meier curves were assessed using the *surdiff()* function and *P*-values are reported on each plot.

Data analysis
-------------

All analyses and plots were generated using the R environment (v3.3.3 (<https://www.R-project.org/>), the R package *ggplot2* (v2.2.1 ([@bib78])), and other packages from the *tidyverse* idiom ([@bib79]) as well as GraphPad Prism software, version 5 (GraphPad Software, Inc, La Jolla, CA, USA). We used the student *t*-test to compare expression levels between tumour and normal tissue. Kaplan--Meier plots were analysed using the Cox proportional hazards model via the *survival* R package. Unless otherwise stated, results are shown as mean±s.d. and *P*-values \<0.05 are considered as statistically significant.

Results
=======

A bioinformatic study identifies *MYO5B* as a potential marker for CRC
----------------------------------------------------------------------

Recently, myosins have gained much interest in cancer research ([@bib53]; [@bib42]). Accordingly, we assessed the relevance of Myosin V family members as novel CRC markers. First, we used a previously established meta-analysis ([@bib41]) of several human CRC data sets (*n*=829 patients) to examine the gene expression of different members of the Myosin V family, namely *MYO5A*, *MYO5B*, and *MYO5C*, in CRC. We found that compared to samples obtained from normal colorectal mucosa, *MYO5A* levels were decreased in adenoma samples but did not vary significantly between cancerous and normal tissue ([Figure 1A](#fig1){ref-type="fig"}). [@bib38]) have previously reported that *MYO5A* expression is increased in metastatic CRC tissues. In that study, the epithelial--mesenchymal transition (EMT) inducer Snail acted as a transcriptional activator of *MYO5A*, positively affecting cell migration and, subsequently, metastasis dissemination. However, using our meta-analysis on 829 patients, we were not able to observe a significant alteration in *MYO5A* expression in metastatic *vs* non-metastatic tissues ([Supplementary Figure 2A](#sup1){ref-type="supplementary-material"}). Further studies are needed to shed light on the expression of MYO5A in CRC. Interestingly, *MYO5B* expression was reduced by ∼52% in tumour tissue compared to normal colorectal mucosa samples ([Figure 1A](#fig1){ref-type="fig"}). *MYO5C* showed a similar decrease in expression ([Figure 1A](#fig1){ref-type="fig"}). In addition, a detailed analysis of *MYO5B* expression during CRC progression suggested that *MYO5B* is downregulated in a stage-dependent manner ([Figure 1B](#fig1){ref-type="fig"}).

Next, we generated ROC curves to determine the predictive power of *MYO5B* expression levels to distinguish cancerous from normal tissue. We observed AUC values of 0.9697 and 0.9284 for *MYO5B* and *MYO5C*, respectively ([Figure 1C](#fig1){ref-type="fig"}). In contrast, and in accordance with the expression data in [Figure 1A](#fig1){ref-type="fig"}, the levels of *MYO5A* did not allow for a clear separation of CRC and normal colorectal mucosa samples (AUC=0.5334; [Figure 1C](#fig1){ref-type="fig"}). The distribution of *MYO5B* gene expression levels shows two distinct, almost non-overlapping, peaks, whereas a certain degree of overlap was still observable for the *MYO5C* peaks ([Figure 1C](#fig1){ref-type="fig"}, inset). In conclusion, its high AUC values as well as its well-separated distribution profile support the use of *MYO5B* as a diagnostic marker. We therefore decided to analyse the clinical relevance of *MYO5B* downregulation in CRC.

MYO5B is downregulated on mRNA and protein level in primary human CRC samples
-----------------------------------------------------------------------------

To validate the findings of our bioinformatic analysis, we assessed the expression of *MYO5B* in snap-frozen human CRC samples from a distinct patient cohort. First, we analysed the gene expression of *MYO5B* in 50 matching CRC and non-tumour bulk tissue samples and found that *MYO5B* expression was significantly lower in the tumour samples ([Figure 2A](#fig2){ref-type="fig"}). To ensure that the expression of *MYO5B* was derived from epithelial cells and not from infiltrated immune or residing stromal cells, we decided to specifically select for a highly pure malignant or normal epithelial cell population by LMD. In a set of 21 laser-microdissected paired samples, which we had already analysed as bulk tissue ([Figure 2A](#fig2){ref-type="fig"}) and which was further complemented by a set of 46 CRC laser-microdissected tumour samples, we could observe that *MYO5B* expression was again significantly decreased in tumour samples, compared to normal colon tissue ([Figure 2B](#fig2){ref-type="fig"}). While examining the paired samples selected by LMD, we could observe a higher expression of *MYO5B* in adjacent non-tumour tissue than in the corresponding tumour samples in 20 out of 21 tested patients ([Figure 2C](#fig2){ref-type="fig"}). Interestingly, laser-microdissected samples allowed for a better separation between CRC and non-tumour samples, suggesting that tumour-microenvironment-derived cells interfere with signals emanating from epithelial cells. To further test the potential applicability of MYO5B as a marker in CRC, we used TMAs to determine its expression on the protein level. First, the specificity of the antibody was verified using cells in which the expression of MYO5B was reduced by short-hairpin-mediated knockdown ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"} and Materials and Methods section). In normal healthy colon epithelium, MYO5B staining is known to be very strong at the apical brush border of the colonic mucosa ([@bib49]). Likewise, we observed a cytoplasmic signal for MYO5B in normal and tumourigenic epithelial cells and identified an increasing gradient ranging from the basal pole to the apex ([Figure 2D](#fig2){ref-type="fig"}, left panel). We then evaluated the staining intensity of MYO5B in 74 paired CRC and non-tumour samples and found that normal counterpart tissue shows a significantly stronger signal when compared to matching tumour samples ([Figure 2D](#fig2){ref-type="fig"}, right panel). To determine whether MYO5B expression correlates with disease progression, we divided our sample set into early (I and II) and late (III and IV) stage groups based on their TNM staging. Late-stage samples showed a dramatic loss of MYO5B expression when compared to both normal epithelial tissue and to samples from early-stage tumours ([Figure 2E](#fig2){ref-type="fig"}), confirming the gradual loss of *MYO5B* observed in the meta-analysis. As the loss of MYO5B is known to contribute to the disruption of cell polarity ([@bib49]), we further investigated its expression in tumours with varying differentiation grades, that is, ranging from well- to low-differentiated tumours. Interestingly, we observed a stepwise reduction in signal intensity from well (histological grade I) to moderately (histological grade II) and poorly (histological grade III) differentiated adenocarcinomas ([Figure 2F](#fig2){ref-type="fig"}). Overall, our results show that MYO5B is stage-dependently downregulated and suggest that it might have a role in CRC progression. Future studies on large independent CRC patient cohorts will help proving the robustness of MYO5B as a prognostic marker in CRC.

Loss of MYO5B expression in CRC is not due to promoter hypermethylation
-----------------------------------------------------------------------

Over the last years, hypermethylation of tumour suppressor genes has been reported in different cancer types ([@bib3]). In a similar manner, *MYO5B* is methylated in both gastric tumours ([@bib12]) and leukaemias ([@bib36]). Thus, we decided to analyse whether promoter methylation could explain the observed downregulation of MYO5B in CRC. To this end, we first investigated the expression of *MYO5B* in CRC cell lines after treatment with DAC, a known demethylating agent. However, DAC treatment resulted in no or only minor changes compared to *MYO5B* basal expression levels ([Figure 3A](#fig3){ref-type="fig"}), suggesting that methylation of its promoter may not be responsible for the observed reduction in MYO5B mRNA and protein expression. However, as DAC unspecifically demethylates the entire DNA, indirect effects may have influenced *MYO5B* expression. Thus, we decided to investigate the methylation status of the CpG sites within the entire promoter sequence via mass array technology. The methylation profile analysis of eight CRC cell lines, eight CRC patients (S1--S8) as well as four matching normal non-tumour samples (SN1--SN4) thereby did not show any tumour-specific methylation (background signal is defined by a methylation signal of \<5%), neither in CRC cell lines nor in primary human tumour samples ([Figure 3B](#fig3){ref-type="fig"}). We completed our study by analysing the methylation status of *MYO5B* in a larger CRC cohort using the TCGA database, which includes methylation data on 295 patients. Eight cytosines in the promoter were assessed for methylation, however and in agreement with our previous data ([Figure 3A and B](#fig3){ref-type="fig"}), we did not observe any difference in methylation between healthy and cancerous tissue ([Figure 3C](#fig3){ref-type="fig"}).

*MYO5B* mutations in CRC patients
---------------------------------

Another reason for reduced expression can be ascribed to the presence of mutations, which can lead to degradation at either RNA or protein level; *MYO5B* mutations have mostly been studied in MVID where inactivating mutations induce defects in the polarisation of cells leading to an intractable diarrhoea and malabsorption ([@bib49]; [@bib74]; [@bib34]; [@bib56]). Recently, a comprehensive human genetic study has further linked *MYO5B* mutations to 20% of previously undiagnosed low CGT cholestasis, an atypical form of MVID ([@bib56]). Most importantly, mutations in *MYO5B* have been identified in the malignant transformation of pheochromocytoma and paraganglioma (PCC/PGL) ([@bib8]; [@bib15]; [@bib80]), unravelling MYO5B as a putative player in PCC/PGL tumourigenesis and potential driver of malignancy. Four mutations in *MYO5B* have been identified: the first one is within the myosin head domain (also called motor domain) and is responsible for actin binding (p.L578P); the second is located in the coiled coil motif of MYO5B (p.V1261G); the two other mutations, p.R1641C and p.G1611S, are found within the globular tail domain of MYO5B, which is mediating RAB11A binding. Along this line, we have performed a mutational analysis of the *MYO5B* gene in CRC patients ([Figure 3D](#fig3){ref-type="fig"}). [Supplementary Table 3](#sup1){ref-type="supplementary-material"} highlights the mutations identified in *MYO5B* among CRC patients and describes their potential functional implication: whereas a number of mutations are silent, some missense and nonsense mutations could clearly affect the stability and function of MYO5B. None of the identified mutations were common to the ones that are associated with the progression from benign to malignant PCC/PGL. Three identified nonsense mutations (p.X253_splice, p.Y287Lfs\*17, and p.S608\*) are located in the motor domain and may affect RNA expression. Similarily to the p.Gln1456X and c.4460-1G\>C mutations that were described by [@bib66]), these mutations may result in nonsense-mediated RNA decay leading to a reduction in the expression of *MYO5B*. A number of other mutations ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}) have a high potential to affect the structure and stability of the protein or even specifically affect the function by interfering with RAB11A interaction. These mutations will generally not affect RNA expression. Overall, only a small subset of patients harbours such mutations (20 of 399 patients), which cannot explain the decreased expression of MYO5B in the majority of CRC patient samples. We therefore concluded that the widespread downregulation of MYO5B mRNA and protein expression in our patient collection is most likely neither due to *MYO5B* promoter methylation nor to inactivating mutations, suggesting that other factors, such as histone modifications, might be responsible for the generic loss of MYO5B expression among all CRC patients. We hope that future studies will allow to elucidate the mechanism underpinning MYO5B downregulation in CRC.

*MYO5B* expression has prognostic value in CRC
----------------------------------------------

To evaluate whether *MYO5B* has prognostic value in CRC, we used publicly available gene expression data of 585 CRC patients (GSE39582) ([@bib46]). We confirmed the downregulation of *MYO5B* in this independent data set, which was not contained in our meta-analysis (data not shown). Next, patients were divided into two groups ('high' or 'low'), based on their *MYO5B* expression, followed by Kaplan--Meier survival analysis. We detected a significant correlation between low *MYO5B* expression and shorter overall ([Figure 4A](#fig4){ref-type="fig"}) and relapse-free ([Figure 4B](#fig4){ref-type="fig"}) survival. Using the same data set GSE39582, we extended our analysis to include CRC staging data and found that in stage I and II (lymph node-negative cancer) patients, both overall ([Figure 4C](#fig4){ref-type="fig"}) and relapse-free ([Figure 4D](#fig4){ref-type="fig"}) survival time were associated with *MYO5B* expression. The strong increase in the statistical power of *MYO5B* to predict relapse-free survival in stage I/II patients compared to all stages confounded (*P*=0.003895 in stage I/II *vs P*=0.014 in stages I--IV altogether) highlights the clinical relevance of *MYO5B* expression in early CRC stages. Indeed, identifying patients at risk for recurrence during the early course of the disease might help clinicians to choose the best treatment plan. It is well known that stage II patients do not all benefit from chemotherapy and that markers able to successfully identify 'high-risk' patients are urgently needed. In addition, we further confirmed the prognostic value of *MYO5B* using a second independent patient cohort (GSE24551 ([@bib65])) that included clinical data from 160 CRC patients ([Figure 4E](#fig4){ref-type="fig"}). Loss of MYO5B has been linked to invasion and motility in gastric cancer cells ([@bib11]), which will ultimately lead to the dissemination of the disease by metastases spreading. Accordingly, we investigated in a data set that contained clinical information on metastasis from 125 CRC patients (GSE28814 ([@bib44])) whether *MYO5*B expression could predict the occurrence of metastasis and, by extension, disease relapse. We found that a patient classification according to their *MYO5B* expression allows for the prediction of metastasis development ([Figure 4F](#fig4){ref-type="fig"}). In conclusion, our data suggest that *MYO5B* expression has a strong prognostic value in CRC patients.

RAB family members *RAB8A* and *RAB25* are downregulated in CRC
---------------------------------------------------------------

MYO5B is known to interact with different members of the RAB family, such as RAB8A, RAB9A, RAB10, RAB11A, and RAB25 ([@bib14]; [@bib29]; [@bib58]) that are essential components of the vesicle trafficking machinery ([@bib32]; [@bib82]). Several of these proteins have recently been identified to exhibit a tumour suppressor role in cancer ([@bib50]; [@bib48]; [@bib72]). To select the most relevant RAB family members in CRC, we analysed the correlation between the expression of *MYO5B* and different RAB family members by performing linear regression analyses using our meta-analysis. Five RAB genes, namely *RAB8A*, *RAB9A*, *RAB10*, *RAB11A*, and *RAB25*, which are known to interact with MYO5B and for which the expression correlated with that of *MYO5B*, were selected for further expression analysis ([Supplementary Figure 2B](#sup1){ref-type="supplementary-material"} and data not shown). Interestingly, all examined RAB family members were significantly downregulated in CRC ([Figure 5A](#fig5){ref-type="fig"}). Furthermore, *RAB8A* and *RAB9A* levels were far lower in adenoma samples than in normal healthy samples ([Figure 5A](#fig5){ref-type="fig"}). This finding may potentially be used as an indicator for pre-malignant tumours, as *RAB8A* and *RAB9A* expression is further reduced over the course of tumour progression ([Figure 5A](#fig5){ref-type="fig"}). Following this, we aimed at determining the suitability of our examined RAB members as potential prognostic markers for CRC. The results obtained were further strengthened by our correlation data, as *RAB8A* and *RAB25* showed the highest AUC values, indicating their suitability as CRC markers ([Figure 5B](#fig5){ref-type="fig"} and [Supplementary Figure 2C](#sup1){ref-type="supplementary-material"}). Finally, we assessed the expression of these adapter molecules in CRC and found that *RAB8A* and *RAB25* were significantly downregulated in our paired tumour/non-tumour data set ([Figure 5C](#fig5){ref-type="fig"}). We may hypothesise that the expression of *MYO5B* and its adapters, *RAB8A* and *RAB25*, is reduced in CRC, potentially contributing to the loss of polarity in epithelial cells and ultimately leading to tumour invasion and disease progression. Interestingly, *RAB25* is methylated in two CRC cell lines (SW480 and SW620) and in patients (TCGA dataset, *n*=295, [Supplementary Figure 3](#sup1){ref-type="supplementary-material"}), which is in line with the epigenetic silencing of *RAB25* observed in other cancer types ([@bib81]; [@bib6]) and the poor prognosis that is associated with low *RAB25* expression in CRC ([@bib50]; [@bib20]).

The combinatorial signature of *MYO5B* with its adapter *RAB8A* has strong prognostic value in CRC
--------------------------------------------------------------------------------------------------

As we identified a correlation between the expression of certain adapters and *MYO5B*, we hypothesised that a combinatorial signature with one or more adapters might further increase the prognostic power, compared to *MYO5B* alone. To analyse this further, we tested a multitude of different combinatorial signatures (*n*=63), carrying out our analysis on the GSE39582 data set (*n*=585 CRC patients). Strikingly, among the 63 different possibilities, the combination of the expression of *MYO5B* and its adapter *RAB8A* showed the highest response ([Figure 6A](#fig6){ref-type="fig"}) and markedly increased the prognostic power compared to *MYO5B* alone, both on overall and on relapse-free survival ([Figure 6B](#fig6){ref-type="fig"}). As *MYO5B* is also associated with the Rac/Rho pathway ([@bib80]), we analysed whether a combinatorial signature of *MYO5B* together with *CDC42*, *RAC1*, or *RHOA* could outperform the single gene expression of *MYO5B* alone or the combinatorial signature, including *MYO5B* and *RAB8A* as well as the other RAB members. While the combinatorial signature of *RAB8A*, *RAB11A*, and *RHOA* outperformed the prognostic value of *MYO5B* expression alone, the combination of *MYO5B* together with the small GTPase *RAB8A* demonstrated the best prognostic value for relapse-free survival ([Figure 6](#fig6){ref-type="fig"} and [Supplementary Figure 4B](#sup1){ref-type="supplementary-material"}).

Discussion
==========

There is a lack of reliable prognostic markers in the current treatment of CRC. Up to now, the prognosis of CRC patients highly depends on tumour staging, which is defined by the degree of tumour penetration through the intestinal wall and the presence of distant metastasis. Nevertheless, patients with an identical TNM stage often differ in terms of treatment response and survival outcome. Consequently, a better classification of the patients is urgently needed to advise clinicians in choosing the best treatment options ultimately leading to increased patient survival. Recently, a combined effort of several different groups has led to a consensus on CRC classification, resulting in the identification of four distinct molecular CRC subtypes with clear biological interpretability ([@bib26]). However, this classification is based on large-scale gene expression analysis and could therefore potentially be difficult to translate into clinical use due to cost issues as well as limitations in sufficient quantity and quality from formalin-fixed paraffin-embedded tissue. Thus, it is vital to identify markers that can easily be used in clinics and that help to stratify patients with different prognosis, thereby identifying 'high-risk' patients. In this study, we examined the expression of Myosin V family members in CRC; MYO5B mRNA and protein expression is reduced in CRC samples and loss of its expression correlates with TNM stage and tumour differentiation grade. Most importantly, we were able to show that *MYO5B* downregulation, alone or in combination with a lower expression of its adapter *RAB8A*, is an independent predictor of shorter overall and relapse-free survival, which may guide oncologists in choosing the best available treatment option for a given patient. In a recent study, the Vermeulen group has used paraffin-embedded primary CRC tissues to classify CRC patients based on the expression of five immunohistochemical markers (CDX2, FRMD6, HTR2B, ZEB1, and KER) and showed an 87% concordance with the transcriptome-based four molecular subtype classification of CRC ([@bib69]). Keeping this in mind, it would be interesting to see whether analysing MYO5B expression could further improve the robustness of immunohistochemical assays.

Increasing evidence suggests that myosins have multiple crucial roles during tumourigenesis ([@bib53]; [@bib42]). Nevertheless, MYO5B, a member of the non-conventional myosins, remains poorly studied in the context of cancer. Dong and colleagues have shown that inactivation of MYO5B in gastric cancer leads to c-Met signalling, thereby enhancing tumour invasion and progression. In addition, they reported a reduced expression of MYO5B and found its promoter to be hypermethylated in 93% of gastric carcinoma samples ([@bib11], [@bib12]). In our study, mass array analysis, a highly quantitative method, was used to assess the methylation pattern of all cytosines within the *MYO5B* promoter. We could not detect any significant methylation, neither in the CRC cell lines nor in the analysed CRC tissue samples, nor could we find any evidence for significant methylation in the TCGA data set. Thus, alternative mechanisms other than promoter methylation seem to be responsible for the downregulation of MYO5B in CRC. Interestingly, *MYO1A* has been shown to be inactivated by genetic mutations in CRC, though restricted to MSI-positive patients ([@bib47]). Similarly, mutations in *MYO5B* were exclusively found in the malignant form of PCC/PGL (Wilzén *et al*, 2016). In our study however, as most CRC patients do not harbour *MYO5B* mutations, inactivating mutations only allow to explain low expression of MYO5B in a small subset of CRC patients, suggesting that other factors, such as histone modifications, might be responsible for the loss of MYO5B expression in cancer.

During tumour progression, the structural proteins of the intestinal brush border lose their expression ([@bib4]; [@bib77]), which correlates with the loss of epithelial architecture and cell differentiation/polarity. Accordingly, EMT, a pre-requisite to tumour invasion and metastasis dissemination, is characterised by the downregulation of epithelial differentiation markers and the loss of cell polarity and tissue organisation ([@bib52]). In agreement with this, we could show that MYO5B expression is decreased in tumours during progression of the disease ([Figure 2E](#fig2){ref-type="fig"}) and upon loss of tissue organisation ([Figure 2F](#fig2){ref-type="fig"}). In addition, our own unpublished data suggest that the induction of EMT correlates with the loss of MYO5B expression, a further possible explanation for the downregulation of MYO5B in CRC. As EMT correlates with the acquisition of cells with stem cell properties ([@bib45]), we may further hypothesise that loss of MYO5B expression is involved in tumour initiation and progression by maintaining cells in an undifferentiated stem-cell-like state. Accordingly, we observed that the differentiation grade of the tumour was dependent on MYO5B expression. Along similar lines, a recent study by [@bib47] uncovered MYO1A to be essential for the polarisation and differentiation of tumourigenic colon cells, demonstrating its tumour suppressor activity in the intestine.

Studies on MVID have demonstrated that MYO5B regulates global intestinal enterocyte polarity ([@bib49]), which is dependent on RAB8A and RAB11A ([@bib34]). Interestingly, Rab GTPases have host protective roles ([@bib32]), including the establishment of endothelial and epithelial barrier integrity ([@bib33]), and bacterial and viral pathogens often hijack the membrane trafficking machinery to facilitate their replication within host cells ([@bib25]). One may therefore speculate that the loss of junctional integrity in enterocytes, which is dependent on MYO5B ([@bib34]), might lead to pathogen infection and to chronic inflammation, one of the main causes of CRC ([@bib24]). Strikingly, we observed a reduced expression of *MYO5B* in inflammatory bowel disease (*P*=1.66 × 10^−3^, own unpublished observation), a chronic inflammatory condition with major defects in epithelial barrier integrity that is associated with an increased risk of CRC ([@bib51]). Future studies will focus on unravelling the mechanism by which loss of MYO5B leads to tumour progression. While the precise molecular mechanisms remain ellusive, our data clearly identify MYO5B, alone or together with its adapter protein RAB8A, as a strong prognostic marker in CRC.
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![**Bioinformatic analysis reveals the potential use of *MYO5B* as a diagnostic marker for CRC.** (**A**) Dot plot showing the log~2~ FC values of the Myosin V family genes in adenoma (beige) and CRC (blue) samples compared to healthy colorectal mucosa samples (grey) in a meta-analysis of different CRC data sets, including 829 patients. Bar represents the mean expression intensity (\*\*\**P*\<0.001, *t*-test corrected for multiple testing). (**B**) *MYO5B* expression according to the different TNM stages in the meta-analysis. Bar represents the mean expression intensity (\**P*\<0.05, \*\*\**P*\<0.001, *t*-test corrected for multiple testing). (**C**) ROC curves with corresponding AUC values for *MYO5A*, *MYO5B*, and *MYO5C* when comparing CRC and healthy samples in the meta-analysis. Distribution of gene expression values for healthy and CRC samples are shown in the insets.](bjc2017352f1){#fig1}

![**Downregulation of MYO5B on mRNA and protein levels in human CRC.** (**A**) *MYO5B* mRNA levels in bulk tissue of matched tumour (CRC, *n*=50) and non-tumour (normal, *n*=50) samples from CRC patients. Data are presented as mean±s.d. (\*\*\**P*\<0.001, paired *t*-test). (**B**) *MYO5*B mRNA levels in laser-microdissected tumour (CRC, *n*=67) and non-tumour (normal, *n*=21) samples. Data are presented as mean±s.d. (\*\*\**P*\<0.001, unpaired *t*-test). (**C**) In 20 out of 21 paired microdissected tumour samples, *MYO5B* mRNA levels were higher in non-tumour tissue compared to the matched tumour sample (\*\*\**P*\<0.001, paired *t*-test). (**D**) Immunohistochemical staining of 74 paired TMAs of CRC patients. Left panel: representative image of MYO5B immunostaining on a section that contains normal (bottom) and cancerous tissue (top). Staining was mainly cytoplasmic and showed the expected accumulation of MYO5B at the apical brush border of normal enterocytes, as well as in tumoural cells in which differentiation was still preserved. Scale bar corresponds to 200 *μ*m. Right panel: quantification of MYO5B staining of matched tumour (CRC; *n*=74) and non-tumour (normal; *n*=74) samples scored according to the staining intensity of MYO5B-positive cells (0=no signal, 1=mild signal, 2=moderate signal, and 3=strong signal). Two sections of cancerous as well as normal counterpart tissue were scored per patient and the mean value was considered. Data are presented as mean±s.d. (\*\*\**P*\<0.001, paired *t*-test). (**E**) Representative pictures (left panel) and quantification (right panel) of immunohistochemical staining of MYO5B in patient samples of different TNM stages. Data are presented as mean±s.d. (\*\**P*\<0.01, \*\*\**P*\<0.001, unpaired *t*-test). Scale bar corresponds to 200 *μ*m. (**F**) MYO5B scoring of TMA samples after classification according to their histological grade. The information was missing for one patient. Data are presented as mean±s.d.; unpaired *t*-test. \**P*\<0.05, \*\**P*\<0.01, and \*\*\**P*\<0.001.](bjc2017352f2){#fig2}

![**Frequently reduced expression of *MYO5B is* neither due to methylation nor mutations in CRC.** (**A**) 5-aza-dC (DAC) treatment does not increase basal *MYO5B* expression in colon cancer cell lines. Data are representative of 2--4 independent experiments and presented as mean±s.d. (**B**) Methylation pattern analysed by mass array technology of eight CRC cell lines as well as eight tumour samples and four matching non-tumour counterparts. Each analysed cytosine is represented by a dot; cytosines with values below 5% were considered as non-methylated. (**C**) Analysis of *MYO5B* methylation in the TCGA data set covering methylation data on 295 tumour and 19 non-tumour samples. (**D**) *MYO5B* mutations in CRC patients. The protein domains and motifs are presented according to [@bib56]), and the RAB8A- and RAB11A-binding sites according to [@bib58]). The dilute domain is also called globular tail domain. IQ=IQ motif, BD=binding domain.](bjc2017352f3){#fig3}

![***MYO5B* is a prognostic marker in CRC patients.** (**A** and **B**) Overall (**A**), *n*=585 and relapse-free (**B**), *n*=574 survival in CRC patients stratified according to *MYO5B* expression in the GSE39582 data set. (**C** and **D**) Overall (**C**) and relapse-free (**D**) survival in early stage (stages I and II) CRC patients stratified according to *MYO5B* expression in the GSE39582 data set. (**E**) Disease-free survival curves for patients with 'high' and 'low' expression levels of *MYO5B* in an independent data set (GSE24551) covering 160 patients. (**F**) Metastasis-free survival based on 'high' or 'low' expression of *MYO5B* in a data set (GSE28814) containing clinical data on metastasis from 125 CRC patients. Patient numbers and associated *P*-values are indicated in the figures.](bjc2017352f4){#fig4}

![**RAB family members *RAB8A* and *RAB25* are downregulated in CRC.** (**A**) Dot plot showing the log~2~ expression intensities of different RAB genes in adenoma (beige) and CRC (blue) samples compared to unmatched healthy colorectal mucosa (grey) samples in a meta-analysis of different CRC data sets, including 829 patients. Bar represents the mean expression intensity (\**P*\<0.05, \*\*\**P*\<0.001, *t*-test corrected for multiple testing). (**B**) ROC curves with corresponding AUC values for RAB genes when classifying CRC and healthy patients in the meta-analysis. Distribution of gene expression values for normal and CRC samples are shown in the insets. (**C**) *RAB8A* and *RAB25* expression levels in bulk tissue of matched tumour (CRC, *n*=50) and non-tumour (normal, *n*=50) samples from CRC patients. Data are presented as mean±s.d.; \**P*\<0.05, \*\*\**P*\<0.001, paired *t*-test.](bjc2017352f5){#fig5}

![**The combination of *MYO5B* expression with its adapter protein *RAB8A* improves the prognostic power of *MYO5B* in CRC.** (**A**) Top 20 significant combinatorial signatures between *MYO5B* and different genes of the RAB family for overall (OS, left) and relapse-free (RFS, right) survival in 585 CRC patients of the GSE39582 data set. Because of space issues, MYO as well as RAB have been omitted from the name description and only the last letters are shown. (**B**) Overall (left) and relapse-free (right) survival in 585 CRC patients stratified according to their combined *RAB8A* and *MYO5B* expression signature in the GSE39582 data set. The dotted line represents the *MYO5B* signature alone, whereas continuous lines represent the combinatorial signature. Patient numbers as well as their *P*-values are indicated in the figure.](bjc2017352f6){#fig6}
